Are you Dr. DiMaio?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 50 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
988102 Nebraska Medical Ctr
Omaha, NE 68198Phone+1 402-559-4186Fax+1 402-559-6018
Summary
- Dr. Dominick DiMaio, MD is a board certified pathologist in Omaha, Nebraska. He is currently licensed to practice medicine in Nebraska, Iowa, and Texas. He is affiliated with OrthoNebraska Hospital, Nebraska Medicine - Nebraska Medical Center, and Nebraska Medicine - Bellevue.
Education & Training
- University of Texas Health Science Center at HoustonResidency, Pathology-Anatomic and Clinical, 1995 - 1998
- McGovern Medical School at UTHealthClass of 1995
Certifications & Licensure
- IA State Medical License 2015 - 2026
- NE State Medical License 2000 - 2026
- TX State Medical License 1997 - 2007
- American Board of Pathology Anatomic Pathology
- American Board of Pathology Dermatopathology
Publications & Presentations
PubMed
- 571 citationsOrganoid profiling identifies common responders to chemotherapy in pancreatic cancerHervé Tiriac, Pascal Belleau, Dannielle D. Engle, Dennis Plenker, Astrid Deschênes
Cancer Discovery. 2018-05-31 - 4 citationsDermatofibrosarcoma protuberans with platelet-derived growth factor-D rearrangement; two cases with morphologically distinct presentations.Katelynn Campbell, Julia A. Bridge, Dominick J. DiMaio, Janice Wilson, Sara C. Shalin
Journal of Cutaneous Pathology. 2021-10-09 - 285 citationsCutaneous melanoma, version 2.2019Daniel G. Coit, John A. Thompson, Mark R. Albertini, Christopher A. Barker, William E. Carson
Journal of the National Comprehensive Cancer Network. 2019-04-01
Press Mentions
- Assessing the Agreement of Light Microscopic Evaluation of Oral Lichen Planus Lesions with Associated Direct Immunofluorescence EvaluationSeptember 22nd, 2023